Enovis CORP 8-K filings

Enovis Corporation announced second-quarter 2026 financial results, showcasing 3% reported sales growth and 5% organic growth, alongside reaffirmed full-year financial outlook.

Enovis Corporation's stockholders approved an amendment to the 2020 Omnibus Incentive Plan, authorizing additional shares and increasing director compensation limits at the May 19, 2026 Annual Meeting.

Enovis Corporation announced first-quarter 2026 results with net sales of $589 million, a 5% increase year-over-year, and reaffirmed its full-year financial outlook.

Enovis Corporation announced its fourth quarter and full year 2025 financial results, reporting significant sales growth but also a substantial non-cash goodwill impairment charge.

Enovis Corporation announced its management team will present at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026.

Enovis Corporation announced the retirement of Senior Vice President and Chief Human Resources Officer Patricia A. Lang, effective April 3, 2026, with Laura Singleton appointed as her successor.

Enovis Corporation has amended its credit agreement, extending the maturity date of its revolving and term loan facilities to December 8, 2030, and enhancing financial flexibility.

Enovis Corporation announced that Executive Vice President, Strategy and Business Development, Daniel A. Pryor, stepped down from his executive role as part of a management restructuring.

Enovis Corporation reported strong third-quarter sales growth and raised its full-year 2025 adjusted EBITDA and EPS guidance, despite a significant non-cash goodwill impairment charge.

Enovis Corporation reported strong second-quarter 2025 financial results with a 7% increase in net sales and raised its full-year 2025 financial guidance for revenue, adjusted EBITDA, and adjusted EPS.

Enovis Corporation held its Annual Meeting of Stockholders on May 21, 2025, and announced the results of voting on three proposals.

Enovis Corporation announces an 8% increase in first-quarter sales and appoints a new CEO, while updating its full-year financial expectations.

Enovis Corporation announces Damien McDonald as the new CEO, effective May 12, 2025, and reaffirms its first-quarter revenue and adjusted EBITDA guidance.

Enovis Corporation announces the retirement of CEO Matthew L. Trerotola, who will transition to an Executive Advisor role for one year following the appointment of his successor.

Enovis reports a 23% increase in fourth-quarter sales and significant adjusted EBITDA margin expansion, driven by strong growth in Reconstructive sales and successful integration of Lima.

Enovis Corporation announces that CEO Matt Trerotola will retire upon the appointment of his successor, with a transition plan in place to ensure a smooth handover.

Enovis Corporation has filed a prospectus supplement for the resale of 971,343 common shares by a former shareholder of LimaCorporate S.p.A., related to the acquisition of Lima.

Enovis Corporation presented at the J.P. Morgan Healthcare Conference, detailing its growth strategy focused on innovation, strategic M&A, and operational excellence.

Enovis Corporation announced a 21% increase in third-quarter sales, driven by a 57% growth in its Reconstructive segment, and raised its full-year adjusted earnings per diluted share guidance.

Enovis Corporation announced a 23% increase in second-quarter sales and significant adjusted margin expansion, driven by acquisitions and strong performance in its international reconstructive segment.

Enovis Corporation filed a prospectus supplement for the resale of 971,343 shares of its common stock by a former shareholder of LimaCorporate, marking the first tranche of shares issued as part of the acquisition.

Enovis Corporation's stockholders approved an amendment to the 2020 Omnibus Incentive Plan, increasing the number of shares available for issuance, and also approved a charter amendment to limit officer liability.

Enovis Corporation announced a strong start to 2024, with first-quarter sales up 27% and adjusted EBITDA margin expansion driven by acquisitions and new product introductions.

Enovis Corporation announced strong fourth-quarter and full-year 2023 results, highlighted by 11% sales growth in Q4 and significant progress in its Reconstructive segment.

Enovis Corporation finalized its acquisition of LimaCorporate S.p.A. on January 3, 2024, and subsequently filed an amended 8-K report including historical financials and pro forma information.